Prevalence and risk factors of drug-resistant tuberculosis in border provinces of Iran

Sahebi, Leyla; Ansarin, Khalil; Farajnia, Safar; Amir, Mohammad; Sabour, Siamak

doi:10.1080/00325481.2015.1069168

Cited by 5 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In Iran (2011), the proportion of MDR-TB cases of new and retreated TB cases were reported to be 5% and 38.3%, respectively [5]. Due to the proximity to countries such as Azerbaijan, Armenia and Pakistan, which are among the 27 countries with the highest MDR-TB burden in world, the control of drug resistance is very pivotal in Iran [7]. …”

Section: Introductionmentioning

confidence: 99%

Patterns of Drug Resistance Among Tuberculosis Patients in West and Northwestern Iran

Sahebi

Ansarin

Mohajeri

et al. 2016

TORMJ

Self Cite

View full text Add to dashboard Cite

Background:Tuberculosis (TB) is the leading cause of morbidity and mortality among chronic infectious diseases.Objective: The goal of this cross-sectional study (2011-2013;2013) was to examine the patterns of TB drug resistance among HIV-negative pulmonary TB patients in regions near the Iranian border. Method: To this end, MTB isolates were harvested from 300 HIV-negative, pulmonary smear-positive TB patients from the northwest and west Iranian border provinces. Isolates were subjected to first and second-line drug susceptibility testing by the 1% proportion method. Demographic and clinical data were provided using a questionnaire and information from patient records. Results were analyzed using SPSS-18.Results:The mean age of the patients was 52.03 years and 54.3% were male. The prevalence of resistance to any TB drug was 13.6% (38 cases). Eleven percent of the new treatment TB group (28 patients) and 40.7% of the retreatment TB group (11 patients) were resistant to all TB drugs. Twelve (4.3%) patients had multidrug-resistant tuberculosis (MDR-TB) (2.38% in the new TB treatment group and 23.1% in the retreatment group). One patient had extensively drug-resistant tuberculosis (XDR-TB). There was a statistically significant relationship between TB drug resistance and smoking (p=0.02) and a history of migration from village to city (p=0.04), also between TB drug resistance and recurrence of TB in patients that had previously received treatment (p<0.001).Conclusion: Knowledge of drug resistance patterns for new and previously treated cases is critical for effective control of MDR-TB in different regions of the country. The burden of MDR-TB in retreatment cases was high. Previous TB treatment was one of the most important mokers and those who had a history of rural to urban migration were at high risk for the occurrence of TB drug resistance.

show abstract

Section: Introductionmentioning

confidence: 99%

Patterns of Drug Resistance Among Tuberculosis Patients in West and Northwestern Iran

Sahebi

Ansarin

Mohajeri

et al. 2016

TORMJ

Self Cite

View full text Add to dashboard Cite

show abstract

“…All these methods are different from each other in terms of cost, sensitivity, turnaround time, expertise of the operator, and the type of mutation they detect. However, the high cost, lack of access in many endemic areas and the need for high expertise to perform and interpret the results have limited their use.in compare, MAS-PCR is a simple , cost -effective and time-consuming method for verifying drug resistance (4,21). According to a study Iran, the prevalence of MDR stain 2020 2013 is estimated at 6.3% which is not compatible with our ndings (22).…”

Section: Discussionmentioning

confidence: 78%

Molecular identification of multiple drug resistance (MDR) strain of Mycobacterium tuberculosis

Hosseinali,

Mohammadshahi,

Teimourpour

et al. 2023

Mol Biol Rep

View full text Add to dashboard Cite

Background and objectives:Isoniazid and rifampin are the rst -line drug against Mycobacterium tuberculosis. Resistance to these important drugs is a serious threat to human public health. Therefore this study aimed at molecular detection of resistance to these valuable drugs.Materials and methods: In this descriptive cross-sectional study, 111 non -duplicated clinical samples including sputum and Bronchoalveolar lavage (BAL) samples were collected from patients referred to Ardabil Health Center between 2017-2020. The samples were rst examined by microscopic method, then their DNA was extracted using the boiling method. Speci c primers and MAS-PCR method were employed for the detection resistance to isoniazid and rifampin drugs and identi cation of MDR strain.Results: of 111 specimens, 15.3% belonged to NTM. In total, the resistance rate to isoniazid and rifampin was 17% and 27% respectively while the resistance rate to isoniazid and rifampin among NTM was 61.54% and 38.46%. Conclusion:In our study, the prevalence of resistance to isoniazid and rifampin among Mycobacterium tuberculosis complex(MTC) and non-tuberculous mycobacteria(NTM) was investigated using the MAS-PCR method. This work highlighted the high anti-tuberculosis resistance rate among NTM compared to MTC strains.

show abstract

“…One of the most important causes of re-infection is treatment failure, which occurs due to poor management of treatment ( 9 ). Prevention of TB re-infection prevents drug resistance in addition to reducing the economic and social burden of the disease ( 10 ).…”

Section: Discussionmentioning

confidence: 99%

Pattern of drug resistant Mycobacterium tuberculosis in the west and northwest of Iran, a meta-analysis

Ansarin¹,

Sahebi²

2022

IJM

View full text Add to dashboard Cite

Background and Objectives: Drug-resistant tuberculosis (Tb) is a major public health issue across the world. Therefore, it is crucial to determine its pattern in different regions of the world. The aim of this study was to review the prevalence of drug resistant TB in the west and northwest of Iran. Materials and Methods: A systematic literature search was performed to identify studies (2010 to 2021) in Google Schol- ar, PubMed, Thomson Reuters, Scientific Information Database (SID), Cochrane Library, and Medical Library (MedLib) databases. The patterns of any drug-resistant Mycobacterium tuberculosis (MTB); resistance to isoniazid (INH), rifampicin (RMP), streptomycin (SMP), ethambutol (EMB), and multiple drug resistance (MDR) were reviewed in tuberculosis in the west and northwest of Iran. Results: In this review, 7 studies met the eligibility criteria for a meta-analysis. The pooled proportion of any drug resistant TB was 13% (CI 95%: 9.0, 17.0) (43.0% in re-treatment group). The pooled prevalence of any drug resistant TB was more than 1.5 times higher in men compared to women (15% vs. 9.0%). The pooled prevalence (%) of resistance to INH, RMP, SMP, EMB and MDR-TB was 11.0%, 12.0%, 13.0%, 6.0%, and 6.0%, respectively. Kermanshah Province (a province in the west of Iran) showed a high prevalence of any type of drug resistance and MDR-TB (15.9% and 20.0%, respectively). Conclusion: It seems that the western provinces of Iran have a different pattern of drug resistance compared to the northwest- ern provinces. Considering the extent of Iran and the neighboring countries, it is recommended that the pattern of tuberculo- sis drug resistance be reviewed separately in different provinces or regions of Iran. Drug resistance in the re-treatment group was more than three times that of all patients with TB drug resistance. The burden of drug resistance reduces significantly with better control and management of TB drug treatment and preventing re-infection.

show abstract

Prevalence and risk factors of drug-resistant tuberculosis in border provinces of Iran

Cited by 5 publications

References 32 publications

Patterns of Drug Resistance Among Tuberculosis Patients in West and Northwestern Iran

Patterns of Drug Resistance Among Tuberculosis Patients in West and Northwestern Iran

Molecular identification of multiple drug resistance (MDR) strain of Mycobacterium tuberculosis

Pattern of drug resistant Mycobacterium tuberculosis in the west and northwest of Iran, a meta-analysis

Contact Info

Product

Resources

About